These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24062201)

  • 1. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients.
    De Stefano R; Frati E; De Quattro D; Menza L; Manganelli S
    Clin Rheumatol; 2014 May; 33(5):707-11. PubMed ID: 24062201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients.
    Lee SH; Lee YA; Hong SJ; Yang HI
    Clin Rheumatol; 2008 Feb; 27(2):179-81. PubMed ID: 17874173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J; McHugh N; Singh A; Wajdula JS; Sato R
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
    Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease.
    Navarro-Compán V; Moreira V; Ariza-Ariza R; Hernández-Cruz B; Vargas-Lebrón C; Navarro-Sarabia F
    Clin Rheumatol; 2011 Jul; 30(7):993-6. PubMed ID: 21373780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population.
    Lian F; Yang X; Liang L; Xu H; Zhan Z; Qiu Q; Ye Y
    Rheumatol Int; 2012 Jun; 32(6):1663-7. PubMed ID: 21387110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC; Van der Heijde DM; Dougados M; Braun J; Cush JJ; Clegg DO; Inman RD; de Vries T; Tsuji WH
    J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
    Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
    Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis.
    Martín-Mola E; Sieper J; Leirisalo-Repo M; Dijkmans BA; Vlahos B; Pedersen R; Koenig AS; Freundlich B
    Clin Exp Rheumatol; 2010; 28(2):238-45. PubMed ID: 20483046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice.
    Arends S; van der Veer E; Kamps FB; Houtman PM; Bos R; Bootsma H; Brouwer E; Spoorenberg A
    Clin Exp Rheumatol; 2015; 33(2):174-80. PubMed ID: 25797228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
    J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
    Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
    Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.
    Borrás-Blasco J; Gracia-Pérez A; Rosique-Robles JD; Casterá ME; Abad FJ
    Expert Opin Biol Ther; 2014 Feb; 14(2):145-50. PubMed ID: 24359492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
    Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
    Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
    Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
    [No Abstract]   [Full Text] [Related]  

  • 17. Low Doses of Etanercept Can Be Effective to Maintain Remission in Psoriatic Arthritis Patients.
    de Stefano R; Frati E; de Quattro D; de Stefano L
    J Clin Rheumatol; 2018 Apr; 24(3):127-131. PubMed ID: 29293113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
    Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF-alpha therapy for ankylosing spondylitis.
    Son JH; Cha SW
    Clin Orthop Surg; 2010 Mar; 2(1):28-33. PubMed ID: 20190998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis].
    Huang F; Zhang J; Zheng Y; Xu JH; Li XF; Wu HX; Chen ZW; Zhao Z; Zhang YM
    Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1043-7. PubMed ID: 22333175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.